Compare Natera Inc. Common Stock (NTRA) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Invesco S&P 500 Low Volatility ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Invesco S&P 500 Low Volatility ETF trades at $74 (market cap $7.06B). The key difference: Natera Inc. Common Stock is far larger — about 8.1× Invesco S&P 500 Low Volatility ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Invesco S&P 500 Low Volatility ETF for 124 Days on average.
| NTRA | SPLV | |
|---|---|---|
Market Cap | $57.03B | $7.06B |
Volume | 1,131,157 | 1,461,921 |
Sector | Health | — |
52-Week High | $425.64 | $77.97 |
52-Week Low | $179.42 | $70.30 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SPLV trades at $72.98, up 0.26% with a bullish technical signal from moving averages, though oscillators show neutral momentum. The ETF's sector allocation to utilities and real estate has lagged the broader market, returning 5% versus the S&P 500's 17% year-to-date. Recent dividend payments of $0.14 provide income stability amid market volatility.
Outlook remains cautious as growth-adjusted valuations appear stretched at 19.5x P/E. Risks include sector concentration and macroeconomic pressures, but SPLV offers defensive exposure during market uncertainty. The neutral analyst stance reflects balanced near-term prospects between stability benefits and performance headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
